Experts

Gregory K. Bell

Group Vice President and Life Sciences Practice Leader

Gregory K. Bell -

After receiving some unfavorable clinical trial results, a global pharmaceutical company decided to abandon launching a product in its development pipeline that had been expected to achieve “blockbuster” status. After the decision was made, the... Read more
CRA consultants were engaged in connection with a class action in which branded and generic pharmaceutical manufacturers were alleged to have delayed market entry of a generic form of a popular drug. Read more